Celgene Corp (NASDAQ:CELG)

CAPS Rating: 4 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Recs

0
Player Avatar BfloBull (98.10) Submitted: 2/3/2010 10:16:25 AM : Outperform Start Price: $58.27 CELG Score: -1.78

M&P

Featured Broker Partners


Advertisement